Key facts
- AbbVie lowered its 2026 profit forecast.
- The profit forecast trim is due to the planned acquisition of Apogee Therapeutics.
- AbbVie exceeded second-quarter earnings expectations.
- Strong sales of immunology drugs contributed to the Q2 earnings beat.
- AbbVie's shares saw a slight decline after the announcement.
AbbVie has announced a slight downward revision of its 2026 profit forecast, a move directly linked to its planned acquisition of Apogee Therapeutics. This strategic acquisition is expected to impact the company's future financial performance, leading to the adjusted outlook.
Despite the revised long-term forecast, AbbVie reported strong second-quarter financial results, exceeding earnings expectations. This outperformance is attributed to the significant success of its immunology drug portfolio, which continues to drive substantial sales. The company's shares experienced a minor decline in the market following the dual announcements of the acquisition's impact on future profits and the strong quarterly performance.
The acquisition of Apogee Therapeutics represents a key strategic move for AbbVie, aiming to bolster its pipeline and future revenue streams. The company's ability to outperform current earnings expectations highlights the ongoing strength and demand for its existing immunology treatments.